The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Mantle cell lymphoma: 2013 Update on diagnosis, risk‐stratification, and clinical management
Abstract
Disease Overview: Mantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood, and bone marrow with a short remission duration to standard therapies and a median overall survival of 4–5 years. Diagnosis: Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t(11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX‐11 or a low Ki‐67 may correlate with a more indolent form of MCL. The differential diagnosis of MCL includes small lymphocytic lymphoma, marginal zone lymphoma, and follicular lymphoma. Risk Stratification: The Mantle Cell Lymphoma International Prognostic Index (MIPI) is the prognostic model most often used and incorporates ECOG performance status, age, leukocyte count, and lactic dehydrogenase. A modification of the MIPI also adds the Ki‐67 proliferative index if available. The median overall survival (OS) for the low risk group was not reached (5‐year OS of 60%). The median OS for the intermediate risk group was 51 months and 29 months for the high risk group. Risk‐Adapted Therapy: For selected indolent, low MIPI MCL patients, initial observation may be appropriate therapy. For younger patients with intermediate or high risk MIPI MCL, aggressive therapy with a cytarabine containing regimen ± autologous stem cell transplantation should be considered. For older MCL patients with intermediate or high risk MIPI, combination chemotherapy with R‐CHOP, R‐Bendamustine, or a clinical trial should be considered. At the time of relapse, agents directed at activated pathways in MCL cells such as bortezomib (NFkB inhibitor) or lenalidamide (anti‐angiogenesis) are approved agents. Clinical trials with Ibruitinib (Bruton's Tyrosine Kinase inhibitor) or Idelalisib (PI3K inhibitor) have demonstrated excellent clinical activity in MCL patients. Autologous or allogeneic stem cell transplantation can also be considered in young patients. Am. J. Hematol. 88:1083–1088, 2013. © 2013 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,461
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., et al. (2008) · Blood · doi:10.1182/blood-2007-06-095331 · Cited by 984
Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Muller-Hermelink, H. K., Smeland, E. B., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00028-x · Cited by 914
Self-citationFisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A. M., et al. (2008) · Blood · doi:10.1182/blood-2008-03-147025 · Cited by 622
O'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.050 · Cited by 577
Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.1825 · Cited by 557
CLASSIFICATION OF NON-HODGKIN'S LYMPHOMAS
Bennett, M., Farrer-Brown, G., Henry, K., Jelliffe, A. M., Gerard-Marchant, R., Hamlin, I., Lennert, K., Rilke, F., Stansfeld, A. G., & Van Unnik, J. A. M. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91786-3 · Cited by 555
Treatment of Older Patients with Mantle-Cell Lymphoma
Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200920 · Cited by 520
Foran, J. M., Rohatiner, A. Z. S., Cunningham, D., Popescu, R. A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P. W. M., Gisselbrecht, C., Reyes, F., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.317 · Cited by 472
Jares, P., Colomer, D., & Campo, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2230 · Cited by 466
Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma
Fernàndez, V., Salamero, O., Espinet, B., Solé, F., Royo, C., Navarro, A., Camacho, F., Beà, S., Hartmann, E., Amador, V., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3419 · Cited by 463
Rummel, M. J., Al-Batran, S. E., Kim, S.-Z., Welslau, M., Hecker, R., Kofahl-Krause, D., Josten, K.-M., Dürk, H., Rost, A., Neise, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.100 · Cited by 441
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Pérez-Galán, P., Dreyling, M., & Wiestner, A. (2011) · Blood · doi:10.1182/blood-2010-04-189977 · Cited by 394
Molecular pathogenesis of mantle cell lymphoma
Jares, P., Colomer, D., & Campo, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61272 · Cited by 382
Howard, O. M., Gribben, J. G., Neuberg, D. S., Grossbard, M. L., Poor, C., Janicek, M. J., & Shipp, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1288 · Cited by 372
Goy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R. R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., DiLiberto, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6121 · Cited by 339
Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn656 · Cited by 336
Ruan, J., Martin, P., Furman, R. R., Lee, S. M., Cheung, K., Vose, J. M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1142 · Cited by 319
Self-citationTiemann, M., Schrader, C., Klapper, W., Dreyling, M. H., Campo, E., Norton, A., Berger, F., Kluin, P., Ott, G., Pileri, S., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05716.x · Cited by 315
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Witzig, T. E., Reeder, C. B., LaPlant, B. R., Gupta, M., Johnston, P. B., Micallef, I. N., Porrata, L. F., Ansell, S. M., Colgan, J. P., Jacobsen, E. D., et al. (2011) · Leukemia · doi:10.1038/leu.2010.226 · Cited by 297
Wang, M., Fayad, L., Wagner-Bartak, N., Zhang, L., Hagemeister, F., Neelapu, S. S., Samaniego, F., McLaughlin, P., Fanale, M., Younes, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70200-0 · Cited by 297
Delarue, R., Haioun, C., Ribrag, V., Brice, P., Delmer, A., Tilly, H., Salles, G., Van Hoof, A., Casasnovas, O., Brousse, N., et al. (2013) · Blood · doi:10.1182/blood-2011-09-370320 · Cited by 270
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
Romaguera, J. E., Medeiros, L. J., Hagemeister, F. B., Fayad, L. E., Rodriguez, M. A., Pro, B., Younes, A., McLaughlin, P., Goy, A., Sarris, A. H., et al. (2003) · Cancer · doi:10.1002/cncr.11096 · Cited by 269
Maris, M. B., Sandmaier, B. M., Storer, B. E., Chauncey, T., Stuart, M. J., Maziarz, R. T., Agura, E., Langston, A. A., Pulsipher, M., Storb, R., et al. (2004) · Blood · doi:10.1182/blood-2004-06-2275 · Cited by 257
Habermann, T. M., Lossos, I. S., Justice, G., Vose, J. M., Wiernik, P. H., McBride, K., Wride, K., Ervin‐Haynes, A., Takeshita, K., Pietronigro, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07626.x · Cited by 244
Self-citationLACTIC ACIDOSIS AND HYPERLACTATÆMIA
Cohen, R. D., Woods, H. F., & Alberti, K. G. M. M. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91784-x · Cited by 222
Ansell, S. M., Inwards, D. J., Rowland, K. M., Flynn, P. J., Morton, R. F., Moore, D. F., Kaufmann, S. H., Ghobrial, I., Kurtin, P. J., Maurer, M., et al. (2008) · Cancer · doi:10.1002/cncr.23580 · Cited by 203
How I treat mantle cell lymphoma
Ghielmini, M., & Zucca, E. (2009) · Blood · doi:10.1182/blood-2009-02-179739 · Cited by 182
Visco, C., Finotto, S., Zambello, R., Paolini, R., Menin, A., Zanotti, R., Zaja, F., Semenzato, G., Pizzolo, G., D'Amore, E. S. G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9842 · Cited by 173
Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype
Bernard, M., Gressin, R., Lefrère, F., Drénou, B., Branger, B., Caulet-Maugendre, S., Tass, P., Brousse, N., Valensi, F., Milpied, N., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402272 · Cited by 167
Histopathology of malignant lymphomas
Berard, C. W., & Dorfman, R. F. (1974) · Clinics in Haematology · doi:10.1016/s0308-2261(74)80005-6 · Cited by 163
Hartmann, E., Fernández, V., Moreno, V. R., Valls, J., Hernández, L., Bosch, F., Abrisqueta, P., Klapper, W., Dreyling, M. H., Hoster, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0410 · Cited by 120
Update on the molecular biology of mantle cell lymphoma
Bertoni, F., Rinaldi, A., Zucca, E., & Cavalli, F. (2006) · Hematological Oncology · doi:10.1002/hon.767 · Cited by 103
LaCasce, A. S., Vandergrift, J. L., Rodriguez, M. A., Abel, G. A., Crosby, A. L., Czuczman, M. S., Nademanee, A. P., Blayney, D. W., Gordon, L. I., Millenson, M. M., et al. (2012) · Blood · doi:10.1182/blood-2011-07-369629 · Cited by 97
Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell Lymphoma
Cohen, B. J., Moskowitz, C., Straus, D., Noy, A., Hedrick, E. E., & Zelenetz, A. D. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109097721 · Cited by 75
Cited by
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
Beà, S., Valdés-Mas, R., Navarro, A., Salaverria, I., Martín-Garcia, D., Jares, P., Giné, E., Pinyol, M., Royo, C., Nadeu, F., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314608110 · Cited by 513
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412096 · Cited by 386
Goy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma
Yan, X., Zhou, Y., Huang, S., Li, X., Yu, M., Huang, J., Wang, J., Ma, Z., Jin, J., Pan, J., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2570-8 · Cited by 12
Metadata
- Authors
- Vose, J. M.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2013-11-22
- Volume
- 88
- Issue
- 12
- Pages
- 1082-1088
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2036266060
- Cited by
- 328
- References
- 43
- FWCI
- 26.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.